Financial Performance - Revenue for the six months ended March 31, 2022, was HKD 89,138,000, an increase of 14.5% compared to HKD 77,567,000 for the same period in 2021[1] - Gross loss for the period was HKD 11,908,000, improved from a gross loss of HKD 31,685,000 in the previous year[1] - Operating loss decreased to HKD 37,197,000 from HKD 52,911,000 year-on-year, reflecting a reduction of 29.8%[1] - The net loss for the period was HKD 37,453,000, compared to a net loss of HKD 53,259,000 in the prior year, indicating a 29.6% improvement[1] - Basic and diluted loss per share was HKD 4.56, down from HKD 6.46 in the same period last year[3] - The company reported a total loss before tax of HKD 37,441 thousand for the six months ended March 31, 2022, compared to a loss of HKD 53,325 thousand for the same period in 2021[28] - The group reported a pre-tax loss of HKD 36,505,000 for the six months ended March 31, 2022, compared to a loss of HKD 51,660,000 in the previous year, indicating an improvement of 29.3%[38] - The group reported a loss of approximately HKD 37.5 million for the six months ending March 31, 2022, compared to a loss of HKD 53.3 million in the same period of the previous year[66] Revenue Breakdown - Revenue from foundation and site preparation works was HKD 48,191 thousand, up 27.1% from HKD 37,870 thousand in the previous year[22] - Other construction works generated revenue of HKD 29,666 thousand, significantly higher than HKD 15,307 thousand in the previous year, marking an increase of 94.5%[22] - Revenue from health product sales decreased to HKD 1,522 thousand from HKD 6,914 thousand, indicating a decline of 78.0%[22] - Revenue from Hong Kong increased to HKD 86,404,000 for the six months ended March 31, 2022, up from HKD 70,579,000 in the same period last year, representing a growth of 22.5%[31] - Revenue from China decreased to HKD 2,734,000 for the six months ended March 31, 2022, down from HKD 6,988,000, reflecting a decline of 60.9%[31] - Revenue from health management and consulting business in China decreased from approximately HKD 7.0 million for the six months ended March 31, 2021, to approximately HKD 2.7 million for the six months ended March 31, 2022, due to COVID-19 and public health emergency policies[55] Assets and Liabilities - Total assets as of March 31, 2022, were HKD 331,593,000, a decrease from HKD 350,575,000 as of September 30, 2021[5] - Total liabilities increased to HKD 189,663,000 from HKD 171,107,000, representing a rise of 10.8%[9] - Cash and cash equivalents decreased to HKD 76,895,000 from HKD 105,911,000, a decline of 27.4%[7] - Trade receivables, net of impairment losses, increased to HKD 33,584,000 as of March 31, 2022, compared to HKD 17,532,000 as of September 30, 2021, representing an increase of 91.6%[44] - The group's current assets net value was approximately HKD 133.0 million as of March 31, 2022, down from HKD 167.0 million as of September 30, 2021[85] - The total equity attributable to the owners of the company was approximately HKD 145.6 million as of March 31, 2022, compared to HKD 182.2 million as of September 30, 2021[85] - The total debt, including lease liabilities, was approximately HKD 2.9 million as of March 31, 2022, down from HKD 4.0 million as of September 30, 2021[85] - The capital debt ratio was approximately 2.0% as of March 31, 2022, slightly decreased from 2.2% as of September 30, 2021[93] Operational Highlights - The group has 44 ongoing construction projects with a total contract value of approximately HKD 780.4 million as of March 31, 2022, compared to 37 projects valued at HKD 742.1 million as of September 30, 2021[51] - The total contract value of ongoing projects increased by approximately 5.5% from the previous period[51] - The group provides construction-related consulting services, including engineering advice, project supervision, and contract management[51] - The group has made progress in its business strategy, including the acquisition of new machinery and equipment to enhance operational capabilities[68] - The group has upgraded its existing hardware and purchased new computer facilities as part of its investment in new information systems[74] - The group has increased capital in two subsidiaries to support its business strategy[68] Employee and Cost Management - The total employee cost for the six months ended March 31, 2022, was approximately HKD 12.8 million, compared to HKD 11.7 million for the same period in 2021[97] - The group had 164 employees as of March 31, 2022, an increase from 62 employees as of March 31, 2021, primarily due to recruitment for the development of health management and consulting services[97] - Administrative and other operating expenses increased by approximately HKD 4.1 million or 17.2%, totaling HKD 28.4 million, primarily due to increased employee costs related to business development in China[63] - The company has committed to using government subsidies for salary expenses and will not reduce employee numbers below a specified level during the designated period[24] - The company plans to continue prudent financial management and cost control in response to the uncertain business environment[56] Corporate Governance - The company has adopted a share option scheme allowing the board to grant options to employees, directors, and major shareholders, with a maximum issuance limit of 10% of the total issued shares as of the listing date[103] - The total number of shares that can be issued under the share option scheme and any other option plans cannot exceed 1% of the company's issued shares within any 12-month period[104] - No share options were granted, exercised, expired, or lapsed under the scheme during the six months ending March 31, 2022[106] - The company has fully complied with the corporate governance code as per the listing rules during the reporting period[107] - The audit committee, established on September 17, 2018, is chaired by an independent non-executive director and includes members with appropriate professional qualifications[108] - The interim condensed consolidated financial statements for the six months ending March 31, 2022, were not audited or reviewed by independent auditors[110] Future Outlook - The company expects that the application of new and revised Hong Kong Financial Reporting Standards will not have a significant impact on future consolidated financial statements[20] - The company is currently evaluating the impact of new accounting standards that will come into effect after January 1, 2023[19] - The group aims to enhance its product portfolio in health management to adapt to market demands during the pandemic[56] - The company is preparing to bid for suitable public sector projects by obtaining additional qualifications and enhancing financial resources[56] - The company is exploring other suitable business opportunities and investment prospects to drive growth[56] - The construction industry and business environment remain challenging due to fluctuating COVID-19 cases[56]
日赢控股(01741) - 2022 Q2 - 季度业绩